NovoCure Limited
NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesotheā¦ read more
Healthcare
Medical Instruments & Supplies
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$11.73
Price+1.21%
$0.14
1Y
Price
Market Cap
$1.311b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-20.4%
EBITDA Margin-22.2%
Net Profit Margin-8.8%
Free Cash Flow MarginRevenue
$630.160m
+8.0%
1y CAGR+1.1%
3y CAGR+2.9%
5y CAGREarnings
-$170.950m
+18.5%
1y CAGR-54.6%
3y CAGR-139.6%
5y CAGREPS
-$1.56
+19.5%
1y CAGR-53.1%
3y CAGR-142.6%
5y CAGRBook Value
$349.441m
$1.246b
Assets$896.434m
Liabilities$700.252m
DebtDebt to Assets
56.2%
-5.2x
Debt to EBITDAFree Cash Flow
-$80.398m
-4.0%
1y CAGR-417.6%
3y CAGR-320.8%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company